The search for new small molecule drugs begins with a deceptively simple question: how does the structure of a molecule determine what it does in a biological system? The answer lies at the heart of structure-activity relationship (SAR) studies, a cornerstone of modern medicinal chemistry. SAR is far more than a technical exercise in molecular tweaking; it is an evolving dialogue between chemistry and biology, where each new compound synthesized provides clues that shape the next design. Medicinal chemists sculpt molecular frameworks to fine-tune potency, selectivity, and pharmacokinetics, while cell biologists translate these chemical changes into biological meaning through assays that reveal how compounds interact with targets and pathways inside living cells. This interplay transforms abstract molecular hypotheses into tangible biological effects, driving the discovery process from initial hits toward optimized drug candidates. In an era defined by high-throughput screening, AI-driven predictions, and mechanistically rich cell-based models, the fusion of medicinal chemistry and cell biology has become more powerful than ever. Together, they form a creative and iterative engine that fuels the rational design of new therapeutics, turning molecular insight into real-world medical innovation.
Small Molecule Drug Discovery
Small molecule drug discovery typically begins with high-throughput screening (HTS), where large libraries of compounds are tested against a biological target to identify initial “hits” that show desired activity. Hits are then validated and optimized through hit-to-lead processes, which involve improving potency, selectivity, and pharmacokinetic properties. Promising leads undergo medicinal chemistry refinement guided by structure-activity relationship (SAR) studies to further enhance efficacy and safety. These optimized compounds are evaluated in in vitro and in vivo assays to assess biological activity, toxicity, and pharmacokinetics. Finally, the most promising molecules are advanced to candidate selection, where a single or small set of compounds is chosen for preclinical development based on overall efficacy, safety, and drug-like properties.
What is Structure-Activity Relationship (SAR)?
In small molecule drug discovery, the structure-activity relationship (SAR) is a foundational concept that describes how changes in a compound’s chemical structure influence its biological activity. Understanding SAR allows medicinal chemists to identify which structural features are responsible for activity, and to modify molecules systematically to improve potency, selectivity, and pharmacological properties.
The SAR refers to the systematic study of how modifications in a molecule’s structure, such as changes in functional groups, substituents, or stereochemistry, affect its biological activity, including binding affinity, efficacy, or toxicity. Essentially, SAR helps determine which parts of a molecule are essential for its desired biological function and how structural changes alter that function. By mapping these relationships, chemists identify the pharmacophore, which represents the minimal structural features required for biological activity, and optimize molecules for improved drug-like behavior.
Medicinal chemists traditionally explore and optimize SAR through a variety of experimental and conceptual approaches. One of the most fundamental methods is systematic structural modification, in which chemists synthesize and test a series of analogs of a lead compound, varying one structural feature at a time. This “one change at a time” strategy allows them to determine which molecular components contribute most to biological activity or toxicity.
Conformational and stereochemical analysis is another essential aspect of SAR. The three-dimensional orientation of a molecule, including its conformation and chirality, profoundly affects how it interacts with biological targets. Medicinal chemists explore different stereoisomers or constrain molecular flexibility through ring closures to lock preferred conformations. Such strategies improve target specificity and reduce off-target binding.
When structural information about the biological target, such as a receptor or enzyme, is available, structure-based drug design (SBDD) becomes an invaluable tool. Using techniques like X-ray crystallography or NMR spectroscopy, chemists visualize how ligands bind to their targets and use this information to guide rational modifications. Structural insights help identify hydrogen bond donors or acceptors, improve shape complementarity, and enhance molecular interactions within the binding site.
Functional group scanning provides another layer of understanding by systematically replacing or removing specific functional groups to determine which ones are essential for activity and which can be modified to improve properties such as solubility or metabolic stability.
Table 1: Traditional SAR approaches
Approach
Description
Goal/Outcome
Systematic analog synthesis
Stepwise chemical modification of lead compounds
Identify essential structural features
Bioisosteric replacement
Substitution with similar functional groups
Improve potency, reduce toxicity
QSAR
Statistical correlation between molecular features and activity
Predict activity of new compounds
Conformational/stereochemical analysis
Study of 3D structure and chirality
Enhance specificity and binding
Structure-based design
Use protein-ligand structures to guide design
Optimize binding interactions
Functional group scanning
Replace or remove specific groups
Identify groups critical for activity
Fragment-based design
Build larger molecules from small active fragments
Create efficient, modular SAR data
The study of structure–activity relationships remains central to medicinal chemistry and continues to be indispensable even in the era of artificial intelligence and computational drug discovery. Traditional SAR approaches provide the experimental and theoretical foundations necessary for understanding molecular interactions. While modern computational techniques accelerate and refine SAR analysis, the principles developed through traditional medicinal chemistry remain vital for designing potent, selective, and safe small molecule therapeutics.
Step-By-Step Process for Advancing Small Molecules During SAR Optimization In Drug Discovery
The constant interface of chemical modifications with testing for biological activity in cell-based assays is central to the SAR process. Once a small molecule is selected for advancement, initial SAR exploration is undertaken to understand how structural changes affect biological activity, primarily through evaluating potency in cell-based assays in vitro. A small set of analogs is designed around the molecular scaffold and tested in both biochemical and cell-based assays. The activity data is analyzed to identify key functional groups and pharmacophores that influence the molecule’s effect. This produces a preliminary SAR map indicating which modifications improve or reduce biological activity. The next step is iterative chemical optimization, which aims to enhance potency, selectivity, and overall drug-like properties. New analogs are designed based on SAR insights, synthesized, and tested in biochemical assays to assess target binding or enzymatic inhibition, as well as in cell-based assays to evaluate functional effects, permeability, and potential toxicity. The results are analyzed to refine the structure-function relationship, and this cycle is repeated iteratively to gradually improve the molecule. Medicinal chemists also consider solubility, metabolic stability, and off-target effects during this phase.
As compounds advance, profiling for absorption, distribution, metabolism, and excretion (ADME) as well as early safety evaluation becomes critical. This includes in vitro metabolism studies, cytotoxicity assays, and assessment of drug-like properties to ensure that the molecules are suitable for in vivo studies. The outcome is an optimized set of compounds with favorable pharmacokinetics and minimal toxicity.
The process flows from initial SAR exploration, iterative optimization, ADME and safety profiling, resulting in the selection of a lead compound. Each step builds on the previous one, with iterative testing in biochemical and cell-based assays guiding the development of increasingly potent, selective, and drug-like molecules.
The Role and Diversity of In Vitro Cell-Based Assays
In vitro cell-based assays serve as a crucial experimental bridge between small molecule chemical modifications, and biological validation. Confirming molecular activity within a biological system remains a mandatory step in drug discovery. These assays measure functional outcomes such as receptor activation, enzyme inhibition, cytotoxicity, or intracellular signaling, thereby providing direct evidence of biological relevance. Table 2: Cell-based assays are essential
Purpose
Description
Confirming predicted bioactivity
Verify that the compound engages the intended target and produces the expected cellular response (e.g., receptor activation, inhibition, signal transduction).
Assessing off-target or cytotoxic effects
Molecular modifications may result in unwanted effects in live cells.
Validating mechanism of action (MOA)
Demonstrate that the compound’s activity occurs through the predicted biological pathway.
Generating new SAR data
Experimental results are analyzed to improve prediction accuracy.
The diversity of cell-based assays used for validation is extensive. Researchers employ both immortalized cell lines and primary cells, depending on the target and mechanism under investigation. Commonly used models include HEK293 or CHO cells for receptor and enzyme assays, cancer cell lines such as MCF-7 or PC-3 for oncology studies, and immune or neuronal cell models for disease-specific investigations. Assay readouts vary widely, encompassing calcium flux measurements, cAMP modulation, reporter gene activation, viability assays, and high-content imaging.
Importantly, medicinal chemistry approaches are often refined and validated across multiple orthogonal assays to ensure robustness. For example, a molecule predicted to inhibit a GPCR may first be tested in a biochemical assay, followed by a cell-based functional assay to confirm downstream signaling inhibition. This multi-assay approach provides the mechanistic confidence necessary to advance compounds to animal models or preclinical development. The diversity of assay types and cell models allows researchers to test small molecules under conditions that approximate physiological complexity while maintaining experimental control and scalability.
The diversity of in vitro assays used in SAR is extremely broad. Assay choice depends on target type, mechanism of action, and desired biological readout. Examples of different classes of cell-based are shown below.
Table 3: Target Engagement Assays. These confirm that the small molecule physically interacts with its target protein inside a cell.
Assay Type
Readout
Example Use
Cellular Thermal Shift Assay
Target stabilization upon binding (detected via Western blot or mass spectrometry)
Confirm intracellular binding of kinase or receptor inhibitors
FRET binding assays
Energy transfer between labeled protein and ligand
Used for GPCRs, kinases, and nuclear receptors
PROTAC degradation assays
Protein degradation levels measured via Western blot or reporter tags
Verify target engagement in degradation-based mechanisms
Table 4: Functional / Phenotypic Assays. Measure the cellular response (e.g., signaling, viability, morphology) rather than just binding.
Assay Type
Readout
Example Applications
Reporter gene assays (e.g., luciferase, GFP)
Transcriptional activity downstream of a target pathway
GPCR or receptor tyrosine kinase activation/inhibition
Calcium flux assays
Intracellular calcium mobilization via fluorescent dyes (e.g., Fluo-4)
Identifying off-target or polypharmacology effects
Table 7: Specialized Cell-Based Systems. For certain targets, highly customized or engineered cell systems are used.
System
Description
Example
Gα15/16-coupled cell lines
Enable calcium signaling readouts from non-native GPCRs
CXCR3, CXCR4 AI-predicted ligands tested in these
CRISPR knock-in/knockout lines
Used to validate on-target effects
Confirm specificity of predicted inhibitors
Primary cell assays (human T cells, hepatocytes)
Physiologically relevant validation
Immunomodulators, metabolic drugs
3D organoids / spheroids
Mimic tissue architecture
Oncology, neurodegenerative disease validation
Conclusion
Structure-activity relationship (SAR) studies remain a cornerstone of small molecule drug discovery, providing a systematic framework for optimizing chemical structure to achieve desired biological outcomes. The iterative and collaborative interaction between medicinal chemistry and cell biology is essential for the success of this process. Medicinal chemists rely on biological data from in vitro and cell-based assays to refine molecular structures and improve potency, selectivity, and pharmacokinetic properties. In turn, cell biologists depend on the evolving chemical series to uncover mechanistic insights, validate target engagement, and assess cellular efficacy and toxicity. This reciprocal exchange of information transforms SAR from a purely chemical exercise into a biologically informed optimization cycle, driving the progression from initial hit compounds to high-quality drug candidates. As modern drug discovery increasingly integrates computational modeling, AI-driven predictions, and high-content cellular assays, the synergy between chemistry and biology will continue to deepen.
Disclaimer:This blog post is intended solely for educational and scientific informational purposes. Any mention of therapeutic drug names, including FDA-approved medications, is for the purpose of accurate reporting and discussion of biomedical research and does not constitute medical advice, endorsement, or promotion. Readers should not interpret the content as a recommendation for any specific treatment. Always consult a qualified healthcare professional for medical advice or treatment decisions.
About Marin Biologic Laboratories
Our Recent Publication/Meeting Presentation on Gene Therapy
Comprehensive Assay Solutions for In Vitro and Cell Based Potency Assays and Pharmacokinetics Studies- Our Expertise
With 30 years of expertise in cell culture, cell-based assays, and preclinical/clinical PK/PD analysis, we specialize in offering assay services essential for a wide variety of therapeutic drug development programs, preclinical studies, IND/BLA applications, and commercialization. Our comprehensive services include both preclinical non-GLP and GLP assays, as well as non-GMP and GMP assays, providing critical support throughout the entire development pipeline.
Watch the following video and explore our latest presentation on the development and validation of potency and pharmacokinetic (PK) assays for AAV vectors, highlighting innovative methodologies and industry-leading expertise.
Contact us to discuss the specifics of your project. Our team of experienced scientists is ready to assist you with tailored solutions to meet your unique needs. Whether you need help with assay development, FDA IND, stability study, lot release approval, or other scientific endeavors, we are here to support you. Contact us to learn more about our cell based assay services
How Long Does It Take to Get Started?
We will initiate your project as soon as the proposal is approved and signed by you. Our streamlined process ensures a quick start, minimizing delays and maximizing efficiency. Fill out the form below to email us or click our live chat option to speak with a MarinBio Scientist and get your project underway.
Can You Help with Assay Development and Validation for FDA IND, Lot Release and Stability Study Approval?
Yes, we have over 30 years of expertise in developing and validating cell based assays for FDA IND, lot release or stability study approval. Our team can also liaise directly with the FDA on your behalf, ensuring a smooth and compliant process. Please contact us to learn more about how we can assist you with your assay development and FDA approval needs.
Do You Need a Custom or Tailored Assay?
MarinBio scientists are experienced and creative in designing, developing, validating assays. Some of the assays we perform are listed below, but there are many more that we created, developed and validated. Give us call so that we may help you.
